Background: Taxanes are commonly used as a standard of care treatment for 1L mTNBC. Few studies have directly compared the effectiveness of nab-paclitaxel and paclitaxel in the real world setting, however. This study investigated the overall survival (OS) of nab-paclitaxel vs. paclitaxel as monotherapy in 1L treatment of mTNBC in routine practice. Methods: A total of 200 patients in the Flatiron Health EHR-derived database were included based on a confirmed diagnosis of mTNBC from 1 Jan 2011 and 31 October 2016 and receipt of nab-paclitaxel or paclitaxel monotherapy as 1L treatment. The primary outcome, OS, was estimated by Kaplan-Meier methods and compared by the logrank test and by univariate and multivariate Cox regression models. Time to next treatment (TTNT) was assessed as a secondary outcome. Results: Compared with pts who received paclitaxel (n ¼ 95), at baseline, those who received nab-paclitaxel (n ¼ 105) were more likely to have been diagnosed at an earlier stage (I-III), have a treatment free 12 months (in pts with recurrent disease), adjuvant treatment with a taxane, a prior diagnosis of neuropathy and coverage by commercial healthcare insurance. Other characteristics were balanced between groups. Over 90% of pts with evaluable dosing data (179 of 195) received weekly doses of either taxane, with 100 mg/m 2 as the most common dose for nab-paclitaxel and 80 mg/m 2 for paclitaxel. Median OS was 11.2 months in pts treated with nab-paclitaxel and 10.8 months in paclitaxel-treated pts (log-rank P ¼ 0.82). The OS hazard ratio (HR) from the adjusted Cox model was 0.90 (95% CI: 0.61, 1.32), indicating a similar risk of death between the two groups. The robustness of this result was confirmed in several sensitivity analyses. TTNT for nab-paclitaxel and paclitaxel was 4.7 and 4.3 months (log-rank P ¼ 0.44), respectively, and did not differ in adjusted analyses (HR ¼ 0.95 [95% CI: 0.65, 1.38]). Conclusions: Nab-paclitaxel and paclitaxel monotherapy demonstrated similar outcomes, suggesting they may be considered interchangeable as 1L treatments for mTNBC.
Background: Anthracycline-or taxane-based regimens are the standard early-line chemotherapy for metastatic breast cancer. However, adverse effects of these treatments, such as neutropenia, peripheral neuropathy, edema, and alopecia, are a concern. The EMBRACE study has shown that eribulin is effective for metastatic breast cancer, even as a late-line treatment. The aim of this study was to investigate the usefulness of eribulin as first-or second-line treatment. Methods: Patients with recurrent HER2-negative breast cancer who had received previous chemotherapy including both an anthracycline and a taxane were eligible for this phase II study. They were randomly allocated to receive eribulin or treatment of physician's choice (TPC) as first-or second-line treatment. TPC was selected in advance from paclitaxel, docetaxel, nab-paclitaxel, and vinorelbine. The primary endpoint was progression-free survival (PFS). Secondary endpoints included time to treatment failure (TTF), response rate (RR), duration of response, and safety. (UMIN000009886). Results: From May 2013 to January 2017, 72 patients were enrolled. The full analysis set comprised data from 58 patients (median age, 58 years; range, 33-82 years); 38 (65.5%) received first-line treatment and 20 (34.5%) received second-line treatment. 43 patients (74.1%) were ER-positive. The per protocol set comprised data from 57 patients. PFS, TTF, RR, and duration of response in both groups are shown in the table. The most common grade 3 or worse adverse events were neutropenia (6/27 [22.2%] in the eribulin group versus 5/31 [16.1%] in the TPC group). The incidence of sensory neuropathy was low in both groups. 
